Meeting
2023 ASCO Annual Meeting
FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO.
Authors
Sylvie Lorenzen
Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, München, Germany
Sylvie Lorenzen , Thorsten Oliver Goetze , Ralf Dieter Hofheinz , Peter C. Thuss-Patience , Tobias Nicolaas Dechow , Jorge Riera-Knorrenschild , Gunter Schuch , Kim Barbara Luley , Christine Koch , Eray Goekkurt , Harald Schmalenberg , Thomas Jens Ettrich , Udo Lindig , Daniel Pink , Michael Bitzer , Claus Bolling , Nils Homann , Sabine Junge , Claudia Pauligk , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03647969
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4045)
DOI
10.1200/JCO.2023.41.16_suppl.4045
Abstract #
4045
Poster Bd #
366
Abstract Disclosures
Similar Posters
First Author: Sylvie Lorenzen
Poster
2019 ASCO Annual Meeting
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
First Author: Salah-Eddin Al-Batran
Poster
2019 Gastrointestinal Cancers Symposium
A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma.
First Author: Aparna Parikh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara